Abdullah Shehab*, Asim Ahmed Elnour, Akshaya Srikanth Bhagavathula, Joseph Pulavelil Kurian, Gazi Hassan, Shareen AlZaabi, Huburt Gilbert and Khalid Al-Rasadi Pages 8 - 16 ( 9 )
Aims: We aim to investigate the efficacy and safety of pitavastatin 4 mg in a population of people living in the United Arab Emirates (UAE).
Background: Pitavastatin is a member of the HMG-CoA reductase inhibitors family which was approved for use in adult subjects with primary hyperlipidemia or mixed dyslipidemia. To date, no published studies have assessed the efficacy and safety of pitavastatin in the United Arab Emirates.
Objective: The main objective of the current study was to investigate the efficacy and safety of pitavastatin in subjects with dyslipidemia for the primary prevention of cardiovascular diseases based on total cardiovascular risk.
Methods: This was a multicentre (four private hospitals) prospective cohort study to analyze data on the use of pitavastatin for dyslipidemia in adult outpatients in Abu Dhabi and Dubai, United Arab Emirates. We have followed up the clinical profiles of subjects in four hospitals for six-weeks during the period from June 2015 to June 2017. Efficacy was based on the evaluation of the mean (± standard deviation) change in low-density lipoprotein cholesterol between baseline and week six after the initiation of pitavastatin therapy. Safety was reported with respect to the incidence of adverse events occurring with the use of pitavastatin and the development of new-onset diabetes.
Results: A total of 400 subjects who were receiving pitavastatin 4 mg were included. The mean age of subjects was 50.7 ±10.8 years; of these, 79.0% were males. At the baseline, the mean level of total cholesterol was 185.4 ±41.5 mg/dL, low density lipoprotein was 154.9 ±48.55 mg/dL, high- -density lipoprotein cholesterol was 40.5 ±11.23 mg/dL and fasting blood glucose was 115.0 (±16.63) mg/dl. At the end of six weeks, low density lipoprotein levels significantly decreased to 112.09 ±41.90 mg/dl (standard mean difference (SMD) (-42.8%), 95% CI: -42.88 [-49.17 to -36.58] mg/dl, P <0.001), while high density lipoprotein levels improved (SMD, 95% CI: 1.77% [0.25 to 3.28] mg/dl, P <0.022). There were 55 subjects (13.7%) who reported various adverse events such as myalgia (7.5%), sleep disorders (2.5%), and myopathy (2.2%). Furthermore, 4 (1.0%) have had developed new-onset diabetes post-six-weeks of initiation of pitavastatin therapy.
Conclusion: Pitavastatin 4 mg showed robust efficacy in reducing LDL-C levels and improving HDL-C levels in subjects with dyslipidemia. The use of pitavastatin was associated with a low discontinuation rate, fewer adverse events, and very limited cases of new-onset diabetes.
Dyslipidemia, efficacy, low density lipoprotein (LDL-C), multicenter, new-onset diabetes, pitavastatin.
Department of Internal Medicine, College of Medicine, United Arab Emirates University (UAEU), Al Ain, Clinical Pharmacy Program, Pharmacy College, Al Ain University, Abu Dhabi Campus,, Department of Internal Medicine, College of Medicine, United Arab Emirates University (UAEU), Al Ain, Department of Cardiology; Lifeline Hospital, Abu Dhabi, Consultant Cardiologist, Gulf Medical Diagnostic Center, Abu Dhabi, Ambulatory Health Services (AHS), Abu Dhabi Heath Services (SEHA), Abu Dhabi, Department of Endocrinology and Diabetology, American Hospital, UAE, Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat